Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.31 |
| ▸ | HTR2C | P28335 | 1/20 | 0.31 |
| ▸ | HRH4 | Q9H3N8 | 1/20 | 0.31 |
| ▸ | AOC3 | Q16853 | 2/20 | 0.31 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18527335 | 0.88 | HTR2A (0.31) | HTR2AHTR2CHRH4 | |
| SCHEMBL6025331 | 0.73 | HTR2A (0.38) | HTR2AHTR2CAOC3MAPTKCNH2 | |
| SCHEMBL18527316 | 0.72 | HTR2A (0.37) | HTR2AHTR2CAOC3MAPTKCNH2 | |
| SCHEMBL3221946 | 0.60 | KMT2A (0.37) | — | |
| SCHEMBL6024522 | 0.60 | HTR2A (0.38) | HTR2AHTR2CMAPT | |
| SCHEMBL18527166 | 0.59 | HTR2A (0.37) | HTR2AHTR2C | |
| SCHEMBL14421619 | 0.57 | SIGMAR1 (0.50) | — | |
| SCHEMBL22502909 | 0.57 | MAPT (0.46) | MAPTKCNH2 | |
| SCHEMBL15778970 | 0.56 | MAPT (0.52) | MAPT | |
| SCHEMBL12551009 | 0.56 | CHKA (0.59) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2017031325-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | FORUM PHARMACEUTICALS INC. (US) | 2017-02-23 | — | — | WO | disclosed |
| US-20170050980-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | DENALI THERAPEUTICS, INC. | 2017-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170050980-A1 | OXADIAZINE COMPOUNDS AND METHODS OF USE THEREOF | PSEN2, SMN1; SMN2, OTC | HTR2A 189/4885HTR2C 215/4885HRH4 1361/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.